These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35366166)

  • 1. Triplet Therapy in Melanoma - Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies.
    Dixon-Douglas JR; Patel RP; Somasundram PM; McArthur GA
    Curr Oncol Rep; 2022 Aug; 24(8):1071-1079. PubMed ID: 35366166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma.
    Albrecht LJ; Dimitriou F; Grover P; Hassel JC; Erdmann M; Forschner A; Johnson DB; Váraljai R; Lodde G; Placke JM; Krefting F; Zaremba A; Ugurel S; Roesch A; Schulz C; Berking C; Pöttgen C; Menzies AM; Long GV; Dummer R; Livingstone E; Schadendorf D; Zimmer L
    Eur J Cancer; 2024 May; 202():113976. PubMed ID: 38484692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
    Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
    Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.
    Kahn AM; Perry CJ; Etts K; Kluger H; Sznol M
    Oncologist; 2024 Apr; 29(4):e507-e513. PubMed ID: 37971411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
    Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
    Front Immunol; 2021; 12():661737. PubMed ID: 34025662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Melanoma with genetic alterations beyond the BRAFV600 mutation: management and new insights.
    Awada G; Neyns B
    Curr Opin Oncol; 2022 Mar; 34(2):115-122. PubMed ID: 35050937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
    Samlowski W; Adajar C
    BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma.
    Schmitt AM; Dumas L; Larkin J
    Expert Rev Anticancer Ther; 2022 Jan; 22(1):17-25. PubMed ID: 34904502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
    Dulgar O; Kutuk T; Eroglu Z
    Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
    Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
    Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
    Babacan NA; Eroglu Z
    Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy.
    Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F
    Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Outcomes in BRAF-Mutated Melanoma Treated with Combined Targeted Therapy or Immune Checkpoint Blockade: Are We Approaching a True Cure?
    Schummer P; Schilling B; Gesierich A
    Am J Clin Dermatol; 2020 Aug; 21(4):493-504. PubMed ID: 32124332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic Therapy for Previously Untreated Advanced BRAF-Mutated Melanoma: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials.
    Devji T; Levine O; Neupane B; Beyene J; Xie F
    JAMA Oncol; 2017 Mar; 3(3):366-373. PubMed ID: 27787543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.
    Lai X; Friedman A
    BMC Syst Biol; 2017 Jul; 11(1):70. PubMed ID: 28724377
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
    Kelley MC
    Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
    Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
    Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF/MEK Inhibition as a Bridge to Immunotherapy for Symptomatic BRAF V600 Melanoma Brain Metastases: A Case Series.
    Strelnikov J; Zhou A; Butt O; Ansstas M; Ansstas G
    J Natl Compr Canc Netw; 2023 Aug; 21(10):991-999. PubMed ID: 37647938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.